title: Polycystic ovary syndrome, the G1691A factor V Leiden mutation, and plasminogen activator inhibitor activity: associations with recurrent pregnancy loss.
abstract: Our specific aim was to assess associations of thrombophilia, hypofibrinolysis, and polycystic ovary syndrome (PCOS) with recurrent pregnancy loss (RPL) (>/=3 consecutive pregnancy losses < 20 weeks gestation). Prospective studies were performed in 33 Caucasian women referred for diagnosis and treatment of PCOS who were subsequently found to have RPL and in 16 Caucasian women referred for diagnosis and treatment of RPL, who did not have PCOS. Cases (PCOS-RPL, RPL without PCOS) were compared with controls (116 healthy Caucasian females) for the G1691A Factor V Leiden, G20210A prothrombin, C677T methylenetetrahydrofolate reductase (MTHFR), plasminogen activator inhibitor 4G/5G, and platelet glycoprotein PL A1A2 gene mutations. Cases were compared with controls (44 healthy adult Caucasian females) for serologic coagulation tests including homocysteine, proteins C, S, free S, antithrombin III, anticardiolipin antibodies IgG and IgM, dilute Russel's viper venom time, activated partial thromboplastin time, Factor VIII, Factor XI, lipoprotein (Lp)(a), and plasminogen activator inhibitor activity (PAI-Fx). The 33 Caucasian women with PCOS subsequently found to have RPL were 10% of a cohort of 322 Caucasian women who had >/= 1 previous pregnancy and had been referred for diagnosis and therapy of PCOS over a 4.3-year period. The Factor V Leiden G1691 mutation was present in 6 of 33 women (18%) with PCOS-RPL and in 3 of 16 women with RPL without PCOS (19%) versus 2 of 116 (1.7%) female controls, Fisher's P (p(f)) =.0016, p(f) =.013. The 33 PCOS-RPL cases also differed from the 44 female controls for high PAI-Fx (>21.1 U/mL), 38% versus 8%, p(f) =. 004. The thrombophilic G1691A Factor V Leiden mutation is associated with RPL in women with and without PCOS; hypofibrinolysis (high PAI-Fx) is also associated with RPL in women with PCOS.
authors.affiliation: Cholesterol Center, Jewish Hospital, Cincinnati, OH 45229, USA.
authors.forename: Charles J
authors.initials: CJ
authors.lastname: Glueck
authors.forename: Ping
authors.initials: P
authors.lastname: Wang
authors.forename: Seref
authors.initials: S
authors.lastname: Bornovali
authors.forename: Naila
authors.initials: N
authors.lastname: Goldenberg
authors.forename: Luann
authors.initials: L
authors.lastname: Sieve
mesh_terms: D000022:Abortion, Spontaneous / Q000235:genetics* / Q000378:metabolism; D000328:Adult; D001777:Blood Coagulation; D001778:Blood Coagulation Disorders / Q000235:genetics; D001835:Body Weight / Q000502:physiology; D005165:Factor V / Q000235:genetics*; D005260:Female; D006579:Heterozygote; D006801:Humans; D006946:Hyperinsulinism / Q000235:genetics / Q000503:physiopathology; D007333:Insulin Resistance / Q000235:genetics / Q000502:physiology; D007621:Karyotyping; D015849:Plasminogen Inactivators / Q000378:metabolism*; D011085:Polycystic Ovary Syndrome / Q000175:diagnosis / Q000235:genetics*; D011247:Pregnancy; D011446:Prospective Studies; D012008:Recurrence; D020133:Reverse Transcriptase Polymerase Chain Reaction; D000090822:Ribosomal Protein L3
chemical_list: D015849:Plasminogen Inactivators; C000716547:RPL3 protein, human; D000090822:Ribosomal Protein L3; C095381:factor V Leiden; D005165:Factor V